The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
PHG swings to Q4 profit as comparable sales jump 7% and orders rise, but shares fall despite double-digit EBITA growth and 2026 outlook.
Koninklijke Philips N.V. (PHG) Q4 2025 Earnings Call Transcript
Roy Jakobs has headed Philips since October 2022 and the company said it would put his re-appointment to shareholders later this year.
Philips benefits from sector-wide valuation tailwinds, anticipated MedTech revival in 2026, and accelerating organic revenue growth. AI integration, highlighted by the SpectraWAVE acquisition, is set to drive higher growth, margin expansion, and capital efficiency for PHG. European healthcare has lagged for three years, leaving valuations attractive; we expect 2026 to mark a re-engagement phase for generalists and a healthier backdrop for the sector.
Philips N.V. (PHG) is rated a conservative 'Buy' with a maintained price target, reflecting 20%+ annualized upside potential. PHG's leadership in imaging, healthcare AI, and a strong moat in diagnosis and treatment underpin the investment case despite historical missteps. Litigation resolution, productivity initiatives, and a 40–50% dividend payout target support margin expansion and forward earnings growth.
Polarean Imaging PLC's (AIM:POLX, OTC:PLLWF) stock popped 12% to 0.14p on Monday after the company cleared a major technical hurdle in its bid to get Xenon-based lung scans into more hospitals. Philips has signed off on Polarean's XENOVIEW 3T chest coil, confirming it plays nicely with the Dutch giant's next wave of 3-tesla MRI scanners.
Polarean Imaging PLC (AIM:POLX, OTC:PLLWF) has cleared a key hurdle in its push to expand the reach of its Xenon-based lung scans, after its dedicated chest coil passed compatibility testing with Philips' latest magnetic resonance imaging systems. The company said Philips had completed its own validation of the XENOVIEW 3T Chest Coil, which was cleared by the US Food and Drug Administration last year.
Koninklijke Philips N.V. ( PHG ) Q3 2025 Earnings Call November 4, 2025 4:00 AM EST Company Participants Durga Doraisamy - Head of Investor Relations Roy Jakobs - President, CEO & Chairman of the Board of Management Charlotte Hanneman - Executive VP, CFO & Member of Board of Management Conference Call Participants Julien Dormois - Jefferies LLC, Research Division Edward Ridley-Day - Rothschild & Co Redburn, Research Division Hugo Solvet - BNP Paribas, Research Division Hassan Al-Wakeel - Barclays Bank PLC, Research Division David Adlington - JPMorgan Chase & Co, Research Division Graham Doyle - UBS Investment Bank, Research Division Veronika Dubajova - Citigroup Inc., Research Division Richard Felton - Goldman Sachs Group, Inc., Research Division Wim Gille - ABN AMRO Bank N.V.
Sales growth and productivity measures at the health-technology company lifted earnings in the third quarter.
Dutch medical technology company Philips reported third-quarter revenue in line with analysts' expectations un Tuesday, citing a strong performance in North America.